ArticleScience (New York, N.Y.)2018
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
12 registry-linked trialsOpen access · greenAbstract readEvaluation Study
In one paragraph
Article in Science (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 12 registered trials, which are not on this map. Cited by 1,242 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,242citing papers in PubMed, 3 pooled it
71.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer
MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)
Pharmacotyping of Patient-derived Pancreatic Cancer Organoids From Endoscopic Ultrasound-guided Biopsy as a Tool for Predicting Oncological Response
Drug Screening of Patient-derived Organoids From Advanced/Recurrent/Metastatic Colorectal Cancer Culture to Personalized Therapy, an Exploratory Research
The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer: a Prospective Multi-center Randomized Controlled Study
Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
A Prospective, Exploratory Study Evaluating the Effectiveness of Treatment Regimens for Locally Advanced/Metastatic Non-resectable Pancreatic Neuroendocrine Tumor (PNET) Guided by in Vitro Drug Sensitivity Testing of Tumor Organoids
Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
Consistency Evaluation of Drug Efficacy Between Clinical Systemic Treatment and Drug Sensitive Test Based on Patient-derived Organoid in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Prospective, Multicenter, Observational Study
Consistency Evaluation of Drug Efficacy Between Clinical Systemic Treatment and Drug Sensitive Test Based on Patient-derived Organoid in Patients With Recurrent/Metastatic Salivary Gland Cancer: A Prospective, Multicenter, Observational Study
MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer: A Prospective Cohort Study
Who cites it
1,242 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,968 citations in OpenAlex.
- Pooled it
- Modeling metastasis and predicting drug response with malignant effusion-derived organoids: a systematic review and quantitative assessment.Journal of translational medicine · 2026Pooled it
- Global research trends and hotspots of colorectal cancer organoids: a bibliometric insight and visualization analysis via multiple databases.Frontiers in oncology · 2026Pooled it
- Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.Cell reports. Medicine · 2026Trial
- Stress-specific 14-3-3-client modules in digestive cancers: an evidence-graded review of adaptive survival and therapy resistance.Cancer biology & therapy · 2026Review
- Trial watch: antibody-drug conjugates in cancer therapy.Oncoimmunology · 2026Review
- Third harmonic generation microscopy reveals structure and mucus dynamics in human airway epithelium models.iScience · 2026Article
- Patient-derived gastric cancer organoids for functional precision oncology: disease-specific bottlenecks and clinical readiness.Translational oncology · 2026Review
- Article
- α7 integrin co-regulates chromatin accessibility and gene expression in HPV-negative head and neck cancer.Signal transduction and targeted therapy · 2026Article
- Patient-Derived Organoids in Functional Precision Oncology: Tumor Modeling, Drug-Response Prediction, and Clinical Translation.Cell biochemistry and function · 2026Review
- Organoids: Current Applications and Future Directions.MedComm · 2026Review
- Construction and application of mammary and breast cancer organoids.Cell insight · 2026Review
- Article
- Tutorial: interrogating biology using organoid technologies.Nature protocols · 2026Review
- The emerging roles of disulfidptosis in cancer.Apoptosis : an international journal on programmed cell death · 2026Review
- Anticancer Peptides: Design Principles, Translational Bottlenecks, and Emerging Opportunities.Molecules (Basel, Switzerland) · 2026Review
- Digital Twins for Targeted Therapy in Head and Neck Cancer: From Molecular Stratification to Resistance-Aware Combination Strategies.Current oncology (Toronto, Ont.) · 2026Review
- Targeting the DNA-repair chromatin-modifier protein SMYD3 as a novel epigenetics-based therapy for gastric cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Deep Learning-Assisted Prioritization of Candidate Drug Targets in Tumors Using Spatial Multi-Omics.Biology · 2026Review
1,182 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
43 authors at 4 institutions in 2 countries.
Georgios VlachogiannisDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0003-3114-8772
Somaieh HedayatDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0002-3547-9184
Alexandra VatsiouCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Yann JaminCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, UK.ORCID 0000-0003-0350-3757
Javier Fernández-MateosDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0002-4949-4131
Khurum KhanDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Andrea LampisDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0002-0665-9100
Katherine EasonDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0001-6903-9067
Ian HuntingfordDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0002-5164-9278
Rosemary BurkeCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.ORCID 0000-0002-0011-9701
Mihaela RataCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, UK.
Dow-Mu KohCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, UK.
Nina TunariuCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, UK.ORCID 0000-0001-6656-3699
David CollinsCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, UK.
Sanna Hulkki-WilsonDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Chanthirika RagulanDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Inmaculada SpiteriCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID 0000-0002-1097-8972
Sing Yu MoorcraftDepartment of Medicine, The Royal Marsden NHS Trust, London, UK.ORCID 0000-0002-3441-1516
Ian ChauDepartment of Medicine, The Royal Marsden NHS Trust, London, UK.ORCID 0000-0003-0286-8703
Sheela RaoDepartment of Medicine, The Royal Marsden NHS Trust, London, UK.
David WatkinsDepartment of Medicine, The Royal Marsden NHS Trust, London, UK.
Nicos FotiadisDepartment of Radiology, The Royal Marsden NHS Trust, London, UK.
Maria BaliCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, UK.ORCID 0000-0002-2697-1329
Mahnaz Darvish-DamavandiDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0003-0226-2621
Hazel LoteDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0003-1172-0372
Zakaria EltahirDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Elizabeth C SmythDepartment of Medicine, The Royal Marsden NHS Trust, London, UK.
Ruwaida BegumDepartment of Medicine, The Royal Marsden NHS Trust, London, UK.
Paul A ClarkeCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.ORCID 0000-0001-9342-1290
Jens C HahneDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Mitchell DowsettRalph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
Johann de BonoDivision of Clinical Studies, The Institute of Cancer Research, London, UK.
Paul WorkmanCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.ORCID 0000-0003-1659-3034
Anguraj SadanandamDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0001-8485-5150
Matteo FassanDepartment of Medicine, Surgical Pathology and Cytopathology Unit, University of Padua, Padua, Italy.ORCID 0000-0001-6515-5482
Owen J SansomCancer Research UK Beatson Institute, Glasgow, UK.
Suzanne EcclesCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.
Naureen StarlingDepartment of Medicine, The Royal Marsden NHS Trust, London, UK.ORCID 0000-0002-1496-6792
Chiara BraconiDepartment of Medicine, The Royal Marsden NHS Trust, London, UK.ORCID 0000-0003-4835-1259
Andrea SottorivaCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID 0000-0001-6709-9533
Simon P RobinsonCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, UK.ORCID 0000-0003-4101-7274
David CunninghamDepartment of Medicine, The Royal Marsden NHS Trust, London, UK.
Nicola ValeriDivision of Molecular Pathology, The Institute of Cancer Research, London, UK. nicola.valeri@icr.ac.uk.ORCID 0000-0002-5426-5683
Institute of Cancer Research · GBCancer Research UK Scotland Institute · GBRoyal Marsden NHS Foundation Trust · GBUniversity of Padua · IT
Funding
Cancer Research UK 11566Cancer Research UK 16464Cancer Research UK 18052Cancer Research UK 21139Cancer Research UK 22897Cancer Research UK 22909Wellcome Trust
Abstract
Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from metastatic, heavily pretreated colorectal and gastroesophageal cancer patients recruited in phase 1/2 clinical trials. Phenotypic and genotypic profiling of PDOs showed a high degree of similarity to the original patient tumors. Molecular profiling of tumor organoids was matched to drug-screening results, suggesting that PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses. We compared responses to anticancer agents ex vivo in organoids and PDO-based orthotopic mouse tumor xenograft models with the responses of the patients in clinical trials. Our data suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.
Indexed as
Drug Resistance, NeoplasmXenograft Model Antitumor AssaysAnimalsAntineoplastic AgentsGastrointestinal NeoplasmsGenomicsHumansMiceNeoplasm MetastasisOrganoidsPhenylurea CompoundsPrecision MedicinePyridinesAntineoplastic AgentsPhenylurea CompoundsPyridinesregorafenib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05177432ClinicalTrials.gov
NCT05189171ClinicalTrials.gov
NCT05196334ClinicalTrials.gov
NCT05304741ClinicalTrials.gov
NCT05351398ClinicalTrials.gov
NCT05767528ClinicalTrials.gov
and 6 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.